Peripheral T-cell Lymphoma
Conditions
Brief summary
The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan
Interventions
DRUGSystemic therapy
Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female participants with a confirmed diagnosis of the specific subtypes of peripheral T-cell lymphoma (PTCL) according to The World Health Organization (WHO) classification of lymphoid neoplasm, 4th edition defined by WHO and International Agency for Research on Cancer (IARC). * Participates aged ≥18 years of age at diagnosis of PTCL. * Participates who have been treated with a systemic therapy for PTCL and have initiated a systemic therapy as a second-line therapy for relapsed or refractory PTCL between April 1, 2018 and March 31, 2023.
Exclusion criteria
* Participates who have medical history of peripheral T-cell lymphoma (PTCL) treatment by unapproved drug in Japan as of 31 March 2024 or off-label drug for PTCL in Japan as of 31 March 2024. * Participates who have medical history of participation to a separately defined registration study for regulatory approval in PTCL. * Participates who have medical history of PTCL treatment in a separately defined clinical study with intervention by on-label regimen for PTCL. * Participates judged to be inappropriate for enrollment in this study by the site investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS) | From baseline until date of death from any cause or last known alive date, assessed up to 6 years |
Secondary
| Measure | Time frame |
|---|---|
| Participant treatment sequence from initial diagnosis | From date of initial diagnosis until death from any cause or last known alive date, assessed up to 6 years |
| Participant baseline demographics | Baseline |
| Participant baseline clinical characteristics | Baseline |
| Frequency of treatment regimen by treatment line | End date of each treatment-line of therapy, assessed up to 6 years |
| Time to next treatment line or death (TTNT) | From date of first-line therapy initiation until death from any cause or last known alive date, assessed up to 6 years |
Countries
Japan
Outcome results
None listed